Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunophenotyping as a guide for targeted therapy.

Pieter Sonneveld1, Rob Pieters

  • 1Department of Hematology, Erasmus MC, Room L407, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands. p.sonneveld@erasmusc.nl

Best Practice & Research. Clinical Haematology
|November 1, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma.

Blood cancer journal·2026
Same author

Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients.

Blood cancer journal·2026
Same author

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

American journal of hematology·2026
Same author

A Phase 2 trial of daratumumab monotherapy in newly diagnosed patients with cardiac stage IIIb AL amyloidosis.

Blood·2026
Same author

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

Nature medicine·2026
Same author

FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial.

Blood advances·2026

Leukemia classification and treatment are advancing with antigen-specific therapies. Targeting specific antigens like CD33 shows promise for acute myeloid leukemia, offering new therapeutic avenues.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Immunophenotyping reveals lineage- and differentiation-specific antigens in leukemia.
  • Disease-specific antigens are crucial for prognosis and targeted therapy.
  • Multidrug resistance proteins (e.g., P-glycoprotein) are linked to poor treatment response.

Purpose of the Study:

  • To explore the role of antigen expression in leukemia classification and therapy.
  • To review emerging antigen-targeted therapies for acute myeloid leukemia.
  • To discuss the potential of novel therapeutic strategies based on leukemia-specific antigens.

Main Methods:

  • Analysis of immunophenotyping data for leukemia classification.
  • Review of clinical trials and studies on targeted therapies.

Related Experiment Videos

  • Investigation of antibody-drug conjugates and tyrosine kinase inhibitors.

    • Main Results:

    • Antigenic expression patterns allow for leukemia classification.
    • Targeted therapies like imatinib and Flt3 inhibitors are under investigation.
    • An antibody-calicheamycin complex targeting CD33 shows clinical activity in relapsed acute myeloid leukemia.

    Conclusions:

    • Antigen-specific therapies represent a promising frontier in leukemia treatment.
    • Targeting specific antigens offers potential for improved prognostic and therapeutic relevance.
    • Further development of antigen-directed approaches is warranted for refractory leukemias.